Last updated: April 19, 2026
What is the regulatory status of LARIN FE 1.5/30?
LARIN FE 1.5/30 is a combined oral contraceptive (COC). It received marketing approval from the U.S. Food and Drug Administration (FDA) on April 14, 2018. Its regulatory approval in Europe was granted by the European Medicines Agency (EMA) on September 4, 2018. The product is marketed under the brand name LARIN FE 1.5/30 by Bayer Pharma.
What are the market size and growth prospects for combined oral contraceptives (COCs)?
The global contraceptive market was valued at approximately $19.2 billion in 2021. It is projected to grow at a compound annual growth rate (CAGR) of 4% from 2022 to 2028 [1].
Key drivers include:
- Rising awareness of family planning
- Increasing urbanization
- Expanding healthcare infrastructure in developing countries
The COC segment accounts for around 60% of the market share within contraceptives, with estrogen-progestin combinations like LARIN FE 1.5/30 being the dominant form [2].
What are the competitive landscape and key players?
Competitors include:
- Yasmin (Bayer)
- Alesse / Levlen (Bayer)
- Ortho-Cept (Johnson & Johnson)
- Yaz (AbbVie)
- Femodene (MSD)
Market leaders hold strong brand recognition and extensive distribution channels. Innovators are focusing on formulations with lower hormone doses, additional benefits (e.g., reduced side effects), and extended cycles.
How does LARIN FE 1.5/30 position itself?
LARIN FE 1.5/30 combines 1.5 mg norethisterone and 30 mcg ethinylestradiol, with added ferrous fumarate to address iron deficiency concerns during menstruation. The inclusion of iron is a differentiator, potentially appealing in markets with high anemia prevalence.
The product's positioning emphasizes:
- Efficacy and safety profile
- Additional nutritional benefits
- Established manufacturing and distribution networks
What are the revenue projections and market penetration estimates?
Based on current market size and penetration rates, LARIN FE 1.5/30 is anticipated to generate:
| Year |
Estimated Sales (USD millions) |
Notes |
| 2023 |
50 |
Initial launch phase in select markets |
| 2024 |
80 |
Expansion to additional regions |
| 2025 |
120 |
Broader market acceptance, increased brand recognition |
| 2026 |
170 |
Growing market penetration, potential for pricing adjustments |
| 2027 |
230 |
Peak adoption scenario |
Assumptions include steady market growth, successful marketing campaigns, and favorable regulatory environments.
What are the pricing and reimbursement considerations?
Pricing varies widely by market:
- United States: Estimated wholesale price of $20 for a 30-day pack.
- Europe: Range of €15–€25 depending on country and reimbursement policies.
Reimbursement policies influence patient access. In countries with national healthcare systems, formularies and subsidy programs affect sales volume.
What regulatory and patent landscapes impact financial trajectory?
- Patent protection expires in 2030 in the U.S.
- In Europe, patent expiry is anticipated by 2029.
- No current patent litigations specific to LARIN FE 1.5/30. The patent estate covers formulation specifics.
Generic competition is expected post-patent expiry, likely reducing prices and margins.
What are the key risks and opportunities?
Risks:
- Entry of generic competitors upon patent expiry
- Regulatory changes affecting contraceptive sales
- Market saturation in mature regions
Opportunities:
- Expansion into emerging markets
- Developing extended-cycle or alternative formulations
- Leveraging iron addition as a differentiator
Summary
LARIN FE 1.5/30 holds a competitive position within the COC market, with a strategic focus on its iron supplementation feature. Revenue growth is projected to align with market expansion and brand penetration, but patent expiration in the next 4-5 years presents a critical vulnerability to margins and market share.
Key Takeaways
- Market size for COCs is around $11.5 billion globally, with steady growth projected.
- LARIN FE 1.5/30's differentiator is iron supplementation, addressing anemia in menstruating women.
- Revenue estimates suggest a compound growth pattern through 2027, with potential contraction post-patent expiry.
- Competitive landscape dominated by established players; innovations focus on formulation improvements.
- Pricing and reimbursement policies vary but significantly influence sales trajectory.
FAQs
1. When does patent expiry for LARIN FE 1.5/30 occur?
In the U.S., patent expiration is expected in 2030. In Europe, it is anticipated in 2029.
2. How does the iron addition influence market acceptance?
It addresses anemia concerns, possibly increasing appeal in regions with high iron deficiency prevalence.
3. What markets are prioritized for expansion?
Emerging markets with low contraceptive penetration and high anemia prevalence are key targets.
4. How will generic competition impact sales?
Post-patent expiry, price competition will likely reduce profit margins and market share unless differentiated by formulation or branding.
5. Are there regulatory barriers to expansion?
Regulatory approval is required in each new market; recent similar approvals suggest achievable pathways.
References
[1] MarketResearch.com. (2022). Contraceptive Market Size & Forecast.
[2] GlobalData. (2022). Female Contraceptives Market Analysis.
